Financial Performance - For the fiscal year ending December 31, 2025, the company reported revenue of RMB 2,039,167, a decrease of 1.5% from RMB 2,070,006 in 2024[3] - Gross profit for the same period was RMB 902,862, down 9.2% from RMB 994,885 in 2024, resulting in a gross margin of 44.3%[3] - Net profit for the year was RMB 403,060, reflecting a decline of 13.8% compared to RMB 467,319 in 2024[3] - Adjusted net profit was RMB 407,389, down 12.6% from RMB 466,092 in the previous year[3] - Basic earnings per share decreased to RMB 0.63, down 12.5% from RMB 0.72 in 2024[3] - The company declared a final dividend of HKD 0.28 per share, a decrease of 27.8% from HKD 0.388 in 2024[3] - The adjusted net profit margin decreased to 20.0%, down from 22.5% in the previous year[3] - The total comprehensive income for the year was RMB 402,458, compared to RMB 464,921 in 2024[5] Assets and Liabilities - Total assets as of December 31, 2025, amounted to RMB 7,553,583,000, an increase from RMB 7,355,053,000 in 2024, representing a growth of approximately 2.7%[7] - Non-current assets totaled RMB 5,480,014,000 in 2025, compared to RMB 5,212,382,000 in 2024, indicating an increase of about 5.1%[6] - Current liabilities decreased to RMB 2,286,535,000 in 2025 from RMB 2,418,192,000 in 2024, reflecting a reduction of approximately 5.4%[6] - Total liabilities slightly increased to RMB 5,057,686,000 in 2025 from RMB 5,041,101,000 in 2024, showing a marginal rise of about 0.3%[7] - Non-current liabilities increased to RMB 2,771,151,000 in 2025 from RMB 2,622,909,000 in 2024, representing a growth of about 5.7%[7] - The company reported a net current liability of RMB 212,966,000 as of December 31, 2025, which includes contract liabilities of RMB 1,026,329,000[10] Revenue Breakdown - The group's income from higher education services for 2025 was RMB 1,621,269 thousand, slightly down from RMB 1,625,566 thousand in 2024[18] - Revenue from educational technology and services decreased to RMB 288,529 thousand in 2025 from RMB 359,687 thousand in 2024[18] - The revenue from higher education services reached RMB 961,224 thousand in 2025, up from RMB 953,754 thousand in 2024, marking a growth of 0.15%[43] - The total revenue from educational technology and services was RMB 57,121 thousand in 2025, slightly down from RMB 58,268 thousand in 2024, showing a decrease of 1.97%[43] - Medical services revenue increased by 46.6% to RMB 83.3 million, contributing 4.1% to total revenue[53] Operational Costs - The total operating costs for the year were RMB 1,075,121 thousand, reflecting a slight increase in costs compared to previous reporting[15] - Operating costs for the fiscal year were approximately RMB 1,136.3 million, an increase of 5.7% year-on-year, mainly due to increased employee compensation and depreciation expenses from school expansion projects[110] - Total other expenses for 2025 amounted to RMB 38,500,000, an increase of 15.1% from RMB 33,228,000 in 2024[22] Investments and Acquisitions - On May 20, 2025, the company acquired approximately 4.2255% equity in Xikang Yunsha for RMB 30.0 million and provided RMB 45.0 million in funding[136] - The company has established Dalian Ruikang Cardiovascular Hospital as a private non-enterprise unit specializing in cardiovascular diseases, registered on December 31, 2021[187] Educational Services and Expansion - The company aims to become a leader in the integrated development of education, healthcare, and elderly care services, focusing on technology-enabled solutions for sustainable growth[51] - The company has successfully transformed its business model to include diversified services, aiming for a sustainable development strategy in the education and healthcare sectors[51] - The company plans to continue expanding its educational offerings and enhancing its technological capabilities in the coming years[54] - The company has developed a comprehensive education service system that combines online and offline resources to empower partner schools and learners[71] Technological Innovations - The company has integrated AI and smart campus technologies to enhance educational governance and effectiveness, including automated attendance and interaction rate identification[69] - The upgraded OpenNEU platform utilizes big data, blockchain, and AI technologies to create an immersive learning environment, enhancing personalized and effective educational support[75] Risk Management - Key risks include reliance on tuition and accommodation fee adjustments, the early-stage nature of the elderly care technology business, and potential impacts from changes in national healthcare policies[157] - The management is responsible for designing and monitoring risk management and internal control systems, with oversight from the board of directors[158] - The group has established a risk management organization to regularly identify, assess, and manage significant risks affecting business objectives[159] Corporate Governance - The company has adhered to the corporate governance code and will continue to review and monitor its governance practices to ensure compliance[173] - The audit committee has reviewed the accounting principles and financial reporting matters for the year ending December 31, 2025[178] - The consolidated financial statements for the year ending December 31, 2025, have been agreed upon by the auditors, confirming consistency with the group's financial reports[179]

EF001 | 其他信息 | | | --- | --- | | 其他信息 | 不適用 | | 發行人董事 | | | | 於本公告日期，董事會包括非執行董事劉積仁博士（董事長）；執行董事溫濤博士；非執行董事（董事長除外）榮新節先生、張霞 | 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 東軟睿新科技集團有限公司 | | 股份代號 | 09616 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月26日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Neutech Group Limited （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9616） 建議修訂章程大綱與細則 及 採納第四次修訂和重列的章程大綱與細則 本公告由本公司根據上市規則第13.51（1）條 刊 發。為 了 符 合 上 市 規 則 的 相 關 要 求，尤 其 是 針 對 上 市 規 則 附 錄A1中 與 對 核 心 股 東 保 護 標 準 有 關 的 修 訂， 該等修訂已於2025年2月10日 生 效，公 司 董 事 會 已 在2026年3月26日舉行的董 事 會 會 議 中 決 議，建 議 對 章 程 大 綱 與 細 則 的 對 應 條 款 進 行 修 改 及 採 納 第 四 次 修 訂 和 重 列 的 章 程 大 綱 與 細 則。建 議 修 訂 及 第 四 次 修 訂 和 重 列 的 章 ...

Neutech Group Limited （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9616） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 劉積仁博士 香 港，2026年3月16日 於 本 公 告 日 期，董 事 會 包 括 非 執 行 董 事 劉 積 仁 博 士（董 事 長）；執 行 董 事 溫 濤 博 士；非 執 行 董 事（董 事 長 除 外）榮 新 節 先 生、張 霞 博 士、張 應 輝 博 士 及 孫 蔭 環 先 生；及 獨 立 非 執 行 董 事 劉 淑 蓮 博 士、曲 道 奎 博 士 及 王 衛 平 博 士。 董事會會議日期 東軟睿新科技集團有限公司（「本集團」）董事會（「董事會」）謹 此 公 布，董 事 會 會 議將於二零二六年三月二十六日（星 期 四）舉 行，藉 以（其 中 包 括）考慮及批准本 集團及其附屬公司截至二零二五年十二月三十 ...

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook for the sector's performance compared to the overall market [5][10]. Core Insights - The report highlights significant developments in the pharmaceutical sector, including a licensing agreement between China National Pharmaceutical Group (Sinopharm) and Sanofi for the JAK/ROCK inhibitor, and the approval of a new indication for Innovent Biologics' BTK inhibitor in China [1][2]. - Performance forecasts for companies such as Crystal Holding and He Yu indicate substantial revenue growth, with Crystal Holding expected to achieve at least 780 million RMB in revenue for 2025, representing a year-on-year increase of approximately 193% [6][7]. Summary by Sections 1. Overseas Pharmaceuticals - Sinopharm and Sanofi have entered into an exclusive licensing agreement for the global development, production, and commercialization of the JAK/ROCK inhibitor, with potential milestone payments totaling up to 1.395 billion USD [2][7]. - Innovent Biologics' BTK inhibitor, Jiepalit (Pirtobrutinib), has received NMPA approval for a new indication in adult patients with chronic lymphocytic leukemia (CLL) who have previously undergone systemic treatment [2][7]. - Roche's BTK inhibitor Fenebrutinib has successfully met primary endpoints in a Phase III trial for relapsing multiple sclerosis, potentially becoming the first effective oral treatment for both relapsing and primary progressive forms of the disease [3][8]. 2. Performance Updates - Crystal Holding anticipates a revenue of no less than 780 million RMB in 2025, with a net profit of at least 100 million RMB, marking a turnaround from losses [6][7]. - He Yu expects to achieve 612 million RMB in revenue for 2025, reflecting a 21% year-on-year growth, with net profit projected at 55 million RMB, a 95% increase [6][7]. 3. Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and others [10]. - It also highlights the importance of monitoring clinical progress in key pipelines for companies transitioning towards innovation [10].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東軟睿新科技集團有限公司(於開曼群島註冊成立之有限公司) 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09616 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,900,000,000 | HKD | | 0.0002 HKD | | 380,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 1,900,000,000 | HKD | | 0.0002 HKD | | 380,000 | 本月 ...

Group 1: Industry Investment Rating - The investment rating for the overseas social services industry is positive, with a focus on the record-high visitor numbers during the Macau Spring Festival [6]. Group 2: Core Insights - The total number of inbound visitors to Macau during the Spring Festival reached 1.554 million, with an average daily visitor count of 173,000, marking a year-on-year increase of 5.5% [6][1]. - Among the inbound visitors, mainland tourists averaged 134,000 per day, reflecting a 7% year-on-year growth, while international visitors averaged nearly 7,900 per day, up by 8% [6][1]. - The hotel occupancy rate during the Spring Festival was 95.6%, with the highest rate of 99.2% recorded on the fourth day of the festival [6][1]. Group 3: Summary by Relevant Sections Overseas Pharmaceuticals - The report highlights significant developments in the pharmaceutical sector, including the announcement of clinical trial results for B7-H3 ADC by Yingensheng and the completion of Phase II trials for UBT251 by Lianbang Pharmaceutical [3][10]. - In 2025, BeiGene reported revenues of $5.343 billion, a 40% increase year-on-year, while adjusted net profits reached $917 million, marking a return to profitability [9][21]. - The report also notes that the average weight loss in the UBT251 trial was as high as 19.7% after 24 weeks, compared to a 2.0% loss in the placebo group [11][10]. Overseas Education - The vocational education sector is experiencing an upswing, with promising enrollment data, particularly for China Oriental Education [5][17]. - The education index saw a decline of 4.9% in the recent week, underperforming the Hang Seng National Enterprises Index by 2.1 percentage points [15]. - The report recommends focusing on China Oriental Education, which is expected to see accelerated enrollment growth due to its strategic adjustments in response to market demands [17][15].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東軟睿新科技集團有限公司(於開曼群島註冊成立之有限公司) 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09616 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,900,000,000 | HKD | | 0.0002 | HKD | | 380,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 1,900,000,000 | HKD | | 0.0002 | HK ...

公司名稱: 東軟睿新科技集團有限公司(於開曼群島註冊成立之有限公司) FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09616 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,900,000,000 | HKD | | 0.0002 HKD | | 380,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 1,900,000,000 | HKD | | 0.0002 HKD | | 380,000 | 本 ...

Group 1: Higher Education Sector - The higher education sector is expected to see a reversal of difficulties due to a combination of bottoming fundamentals and policy advancements, with a focus on improving educational quality and encouraging the expansion of high-quality private colleges [5][6] - The reintroduction of profit-oriented classification management in Hunan Province in 2025 may serve as a pilot for nationwide implementation, providing a stable policy environment for private colleges to expand and meet the growing demand for higher education [5][6] - Key indicators of educational quality, such as student-to-teacher ratios and per-student funding, have met standards after five years of increased investment, suggesting that the investment cycle is peaking and operational efficiency in higher education companies is likely to recover [5][6] - Companies to watch in this sector include Yuhua Education, Zhongjiao Holdings, New Higher Education, China Kepei, Neusoft Ruixin, Xijiao International Holdings, and Zhonghui Group [5][6] Group 2: Vocational Education Sector - The demand for vocational training is surging, driven by an increasing number of university graduates and high school students entering the labor market, leading to a projected market size of 80 billion yuan in 2025 with a penetration rate of only 5% [6][7] - The youth unemployment rate, particularly among those aged 16 to 24, is higher than the urban average, indicating a growing need for vocational skills training [6][7] - Companies to focus on in the vocational education sector include China Oriental Education and Fenbi [6][7] Group 3: Education Industry Trends - The education industry has undergone significant changes due to the "double reduction" policy, resulting in a 96% reduction in capacity in the academic training sector, with a limited number of operational licenses being redistributed [7] - The shift towards competency-based training is gaining momentum, with institutions leveraging their operational qualifications to expand their market share through non-academic training services [7] - The industry is moving towards a "franchise" model, which is expected to enhance revenue and profit growth for compliant institutions [7] Group 4: Investment Recommendations - The report recommends focusing on Hong Kong-listed vocational education companies, particularly China Oriental Education, which is adapting its operational strategy to cater to the needs of high school graduates [9] - In the higher education sector, the potential reintroduction of profit-oriented options is expected to enhance the revenue-sharing certainty for private colleges, with companies like Yuhua Education, Zhongjiao Holdings, and China Kepei being highlighted for their growth potential [9] - The report also suggests monitoring Chinese education companies listed in the US, such as New Oriental, TAL Education, and others, which are showing strong enrollment data [9]